Drugs / VIDUPIPRANT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01137565 | Jun 2010 → Jan 2011 | asthma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT01124279 | May → Aug 2010 | — | Amgen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01018550 | Oct 2009 → Dec 2010 | asthma | Amgen | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIDUPIPRANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL1951575 ↗ |
| Known as | AMG 853 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01018550 ↗ |
| Action | Inhibit | “G protein-coupled receptor 44 antagonist” CHEMBL1951575 ↗1“Prostanoid DP receptor antagonist” CHEMBL1951575 ↗ |
| Modality | Small molecule | — CHEMBL1951575 ↗ |
| Target | PTGDR | “Prostanoid DP receptor antagonist” CHEMBL1951575 ↗ |
| Target | PTGDR2 | “G protein-coupled receptor 44 antagonist” CHEMBL1951575 ↗ |